2019
DOI: 10.3892/ol.2019.10596
|View full text |Cite
|
Sign up to set email alerts
|

An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer

Abstract: The survival rate of patients with pancreatic cancer is between 3 and 5%. The neddylation pathway is overactive in multiple cancer types and is associated with poor prognosis. In recent years, the neddylation process has become a popular research target for the development of novel cancer therapies. However, the activation level of the pathway, and whether its targeting sensitizes pancreatic cancer cells to cisplatin treatment is currently unclear. In the present study, using reverse transcription-quantitative… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
16
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(20 citation statements)
references
References 27 publications
3
16
0
Order By: Relevance
“… 20 The neddylation pathway is reported to be overactivated in multiple cancer types, including liver, lung and colon cancer, and its overactivation indicates poor prognosis. 23 In the present study, the expression profiles of key neddylation genes were analysed in TCGA samples using an online server.…”
Section: Discussionmentioning
confidence: 99%
“… 20 The neddylation pathway is reported to be overactivated in multiple cancer types, including liver, lung and colon cancer, and its overactivation indicates poor prognosis. 23 In the present study, the expression profiles of key neddylation genes were analysed in TCGA samples using an online server.…”
Section: Discussionmentioning
confidence: 99%
“…A deep understanding of the principle and mechanism of these posttranslational modifications can also potentially provide new therapeutics for the cancer patients. The inhibitor of Neddylation E1 enzyme NAE-MLN4924 has been developed and displays dramatic inhibition of hematological malignancies and solid tumors [150][151][152][153][154][155][156][157][158][159][160][161]. Multiple Phase I clinical study of MLN4924 are undergoing [162][163][164][165][166].…”
Section: Discussionmentioning
confidence: 99%
“…A primary disease for consideration would be cancer where dysregulated biochemical pathways are commonly detected. Increased NEDD8 levels along with increased levels of enzymes in the NEDD8 activation and conjugation pathway such as NAE1 have been detected in numerous cancer types, such as pancreatic cancer [103], osteosarcoma [104], bladder [105], and colorectal cancers [106] to name but a few. Interestingly, in the case of colorectal cancers, a non-canonical target of NEDD8 was identified [106].…”
Section: Alterations To Nedd8 Levels In Cells Under Physiological Conditionsmentioning
confidence: 99%